Clinical Trial Update: 90Y-labelled Anti-CD66 ab in Childhood High Risk Leukaemia [Phase 2]

View source ↗

Summary

Phase 2 trial update for a 90Y-labelled anti-CD66 antibody in childhood high-risk leukemia is reported.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia

Drugs mentioned

• 90Y-labelled anti-CD66 antibody (90Y-labelled anti-CD66)

Snippet

Sponsor: Great Ormond Street Hospital for Children NHS Foundation Trust | Conditions: Leukemia | Phase 2 | Status: UNKNOWN